Kyverna Therapeutics (KYTX) Competitors $4.12 +0.04 (+0.98%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KYTX vs. TRDA, ABUS, DNTH, CRMD, TECX, PHAT, EXAI, ORIC, ANAB, and STOKShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), Dianthus Therapeutics (DNTH), CorMedix (CRMD), Tectonic Therapeutic (TECX), Phathom Pharmaceuticals (PHAT), Exscientia (EXAI), ORIC Pharmaceuticals (ORIC), AnaptysBio (ANAB), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Entrada Therapeutics Arbutus Biopharma Dianthus Therapeutics CorMedix Tectonic Therapeutic Phathom Pharmaceuticals Exscientia ORIC Pharmaceuticals AnaptysBio Stoke Therapeutics Kyverna Therapeutics (NASDAQ:KYTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability. Is KYTX or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Kyverna Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Entrada Therapeutics 25.53%16.11%10.39% Does the MarketBeat Community prefer KYTX or TRDA? Entrada Therapeutics received 6 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Entrada Therapeutics an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% Entrada TherapeuticsOutperform Votes1680.00% Underperform Votes420.00% Which has better earnings & valuation, KYTX or TRDA? Entrada Therapeutics has higher revenue and earnings than Kyverna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M25.30-$60.37MN/AN/AEntrada Therapeutics$129.01M5.20-$6.68M$1.5911.28 Does the media refer more to KYTX or TRDA? In the previous week, Kyverna Therapeutics had 14 more articles in the media than Entrada Therapeutics. MarketBeat recorded 16 mentions for Kyverna Therapeutics and 2 mentions for Entrada Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.30 beat Entrada Therapeutics' score of -0.30 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in KYTX or TRDA? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend KYTX or TRDA? Kyverna Therapeutics presently has a consensus price target of $25.71, indicating a potential upside of 524.13%. Entrada Therapeutics has a consensus price target of $24.00, indicating a potential upside of 33.85%. Given Kyverna Therapeutics' higher probable upside, research analysts clearly believe Kyverna Therapeutics is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEntrada Therapeutics beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.86M$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E RatioN/A45.25134.3717.77Price / Sales25.30360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / BookN/A3.734.674.68Net Income-$60.37M-$41.63M$119.07M$226.08M7 Day Performance-14.17%-4.73%-1.83%-1.04%1 Month Performance-20.77%-6.53%-3.62%1.04%1 Year PerformanceN/A25.63%31.63%26.28% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics2.4324 of 5 stars$4.12+1.0%$25.71+524.1%N/A$177.86M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpTRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$664.95M$129.01M11.28110ABUSArbutus Biopharma2.7966 of 5 stars$3.44-1.4%$5.50+59.9%+87.0%$661.33M$18.14M0.0073Analyst ForecastDNTHDianthus Therapeutics1.5021 of 5 stars$20.77-6.7%$46.43+123.5%+78.7%$659.12M$2.83M0.0080CRMDCorMedix2.6681 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$651.67M$12.26M-13.3230Insider TradeHigh Trading VolumeTECXTectonic Therapeutic3.5107 of 5 stars$44.03+7.8%$72.25+64.1%N/A$649.58MN/A-7.48120Analyst ForecastGap UpHigh Trading VolumePHATPhathom Pharmaceuticals2.3223 of 5 stars$8.73-6.8%$22.50+157.7%+17.8%$640.70M$680,000.00-1.53110EXAIExscientia1.9994 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$17.07M-3.21280News CoverageORICORIC Pharmaceuticals4.1871 of 5 stars$8.74-1.7%$18.29+109.2%+22.4%$627.34MN/A0.0080Analyst RevisionANABAnaptysBio2.486 of 5 stars$20.31+1.7%$54.64+169.0%+40.0%$618.03M$17.16M-3.28100STOKStoke Therapeutics3.8396 of 5 stars$11.31-2.6%$20.83+84.2%+171.2%$614.95M$8.78M0.00100 Related Companies and Tools Related Companies TRDA Alternatives ABUS Alternatives DNTH Alternatives CRMD Alternatives TECX Alternatives PHAT Alternatives EXAI Alternatives ORIC Alternatives ANAB Alternatives STOK Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KYTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYTX Stock Alerts